Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

It may have been a short trading week, but Cathie Wood kept busy with her long positions. The founder and CEO of Ark Invest was actively making moves across her collection of ETFs, buying and in some cases selling investments. Let's talk about some of the latest purchases.

Ark was a buyer of Tesla Motors (NASDAQ: TSLA), SoFi Technologies (NASDAQ: SOFI), and Recursion Pharmaceuticals (NASDAQ: RXRX) on Thursday. Tesla shares fell more than 7% on the final trading session ahead of the Independence Day market holiday. SoFi and Recursion are trading 44% and 47% below their 52-week highs, respectively. Wood can be aggressive when it comes to growth investing, so let's take a closer look at these three stocks.

Image source: Getty Images.

1. Tesla Motors

The world's most valuable automaker by market cap is also Wood's largest position. Wood has a $1 billion position in Tesla across all of Ark's ETFs. Tesla stock tumbled 7.5% on Thursday after posting its production and delivery results for the second quarter.

Despite the market's uninspired reaction, the numbers were better than expected. Tesla delivered 480,126 vehicles through April, May, and June, a 25% increase from the 384,122 sedans and Cybertrucks it moved a year earlier. It's the strongest quarter for Tesla deliveries since the third quarter of last year, when the 497,099 vehicles delivered were fueled by the expiration of federal tax credits in the U.S. of up to $7,500. Analysts had been forecasting only 406,024 deliveries a week earlier.

Tesla's jump wasn't the result of a turnaround in U.S. sales. It was a sharp spike in fuel prices that sparked demand across Europe. Investors will take it. After its first year of declining revenue in 2025, the positive rebound in the first quarter wasn't a fluke.

It's also worth noting that Tesla produced only 451,758 vehicles during the quarter. After back-to-back periods of producing more units than it could deliver, Tesla cleared out some of its excess inventory.

The strong deliveries don't guarantee a blowout performance when Tesla reports its second-quarter results on July 22. There was heavy promotional activity to move cars, particularly in Europe. Revenue should come in strong, but will margins suffer as a result of the incentives provided to improve its inventory situation? Wood seems to think that Tesla will do just fine.

2. SoFi Technologies

Here's a fun fact about digital branchless bank SoFi Technologies: Ark added to its stake in the company every single trading day this week. SoFi has grown into a platform with 14.7 million members, a 35% jump over the past year.

Are you familiar with the Rule of 40? It's a metric used primarily to gauge the growth health of software-as-a-service companies, but it also applies to subscription-based fintech platforms. SoFi continues to kill it on that front. To calculate the score, take a company's reported or adjusted revenue growth, which in SoFi's case was 41% in adjusted top-line growth for its latest quarter. Then add a cash flow profitability metric, which for SoFi is its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). Its adjusted EBITDA margin was 31% for the quarter, giving it a score of 72. Anything above 40 is a sign of a fast-growing company that is getting the job done without sacrificing its operating efficiency. SoFi has been holding up well north of 40 on this front for more than four years.

The shares aren't cheap, even after SoFi stock's 30% decline in 2026. It's currently trading for 31 times forward earnings and 23 times next year's analyst profit target. This is reasonable given its strong growth, but it's also high among financial services stocks.

3. Recursion Pharmaceuticals

Finally, we have Recursion Pharmaceuticals. It's one of the smaller companies in Ark's portfolio, with a market cap of $2 billion. It also trades at a small price, just below $4 per share. Ark owns roughly $115 million of the stock, so more than 5% of all shares outstanding.

Recursion is using artificial intelligence to reinvent the drug discovery process. The clinical-stage techbio company has just $66 million in trailing revenue, and losses have widened with every passing year. This isn't a bet that will pay off right away. It has already attracted some notable investors and believers, and they know they'll have to wait for a major windfall. Wood isn't known for her patience, but she's certainly a believer right now.

Rick Munarriz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy.